Submissions from 2024
Successful Crizotinib-targeted Therapy of Pediatric Unresectable ERC1::ALK Fusion Sarcoma., Megan L Wood, Julie C Fanburg-Smith, James M Brian, Jason C White, Jonathan L Powell, and Andrew S Freiberg(Article)
Clinical characteristics, treatment, and outcomes of provoked acute cerebral sinovenous thrombosis in patients <21 years old: findings from the Kids-DOTT Multinational>Trial., Gary M Woods, Alexandra Miller, Maua Mosha, Christoph Male, Anupam Verma, Nicole Kucine, Christine Sabapathy, Kisha Beg, Sanjay Ahuja, Deepti Raybagkar, Kerry Hege, Clara Lo, Rukhmi Bhat, Thomas Abshire, and Neil A Goldenberg(Article)
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells., Maxim Yankelevich, Archana Thakur, Shakeel Modak, Roland Chu, Jeffrey Taub, Alissa Martin, Dana Schalk, Amy Schienshang, Sarah Whitaker, Katie Rea, Daniel W Lee, Qin Liu, Anthony F Shields, Nai-Kong V Cheung, and Lawrence G Lum(Article)